Details

Autor(en) / Beteiligte

• Fink, Ericka L.
• Robertson, Courtney L.
• Wainwright, Mark S.
• Roa, Juan D.
• Lovett, Marlina E.
• Stulce, Casey
• Yacoub, Mais
• Potera, Renee M.
• Zivick, Elizabeth
• Holloway, Adrian
• Nagpal, Ashish
• Wellnitz, Kari
• Czech, Theresa
• Even, Katelyn M.
• Brunow de Carvalho, Werther
• Rodriguez, Isadora Souza
• Schwartz, Stephanie P.
• Walker, Tracie C.
• Campos-Miño, Santiago
• Dervan, Leslie A.
• Geneslaw, Andrew S.
• Sewell, Taylor B.
• Pryce, Patrice
• Silver, Wendy G.
• Lin, Jieru Egeria
• Vargas, Wendy S.
• Topjian, Alexis
• Alcamo, Alicia M.
• McGuire, Jennifer L.
• Domínguez Rojas, Jesus Angel
• Muñoz, Jaime Tasayco
• Hong, Sue J.
• Muller, William J.
• Doerfler, Matthew
• Williams, Cydni N.
• Drury, Kurt
• Bhagat, Dhristie
• Nelson, Aaron
• Price, Dana
• Dapul, Heda
• Santos, Laura
• Kahoud, Robert
• Francoeur, Conall
• Appavu, Brian
• Guilliams, Kristin P.
• Agner, Shannon C.
• Walson, Karen H.
• Rasmussen, Lindsey
• Janas, Anna
• Ferrazzano, Peter
• Farias-Moeller, Raquel
• Snooks, Kellie C.
• Chang, Chung-Chou H.
• Yun, James
• Schober, Michelle E.

Titel

Prevalence and Risk Factors of Neurologic Manifestations in Hospitalized Children Diagnosed with Acute SARS-CoV-2 or MIS-C

Ist Teil von

• Pediatric neurology, 2022-03, Vol.128, p.33-44

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• Our objective was to characterize the frequency, early impact, and risk factors for neurological manifestations in hospitalized children with acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or multisystem inflammatory syndrome in children (MIS-C). Multicenter, cross-sectional study of neurological manifestations in children aged <18 years hospitalized with positive SARS-CoV-2 test or clinical diagnosis of a SARS-CoV-2-related condition between January 2020 and April 2021. Multivariable logistic regression to identify risk factors for neurological manifestations was performed. Of 1493 children, 1278 (86%) were diagnosed with acute SARS-CoV-2 and 215 (14%) with MIS-C. Overall, 44% of the cohort (40% acute SARS-CoV-2 and 66% MIS-C) had at least one neurological manifestation. The most common neurological findings in children with acute SARS-CoV-2 and MIS-C diagnosis were headache (16% and 47%) and acute encephalopathy (15% and 22%), both P < 0.05. Children with neurological manifestations were more likely to require intensive care unit (ICU) care (51% vs 22%), P < 0.001. In multivariable logistic regression, children with neurological manifestations were older (odds ratio [OR] 1.1 and 95% confidence interval [CI] 1.07 to 1.13) and more likely to have MIS-C versus acute SARS-CoV-2 (OR 2.16, 95% CI 1.45 to 3.24), pre-existing neurological and metabolic conditions (OR 3.48, 95% CI 2.37 to 5.15; and OR 1.65, 95% CI 1.04 to 2.66, respectively), and pharyngeal (OR 1.74, 95% CI 1.16 to 2.64) or abdominal pain (OR 1.43, 95% CI 1.03 to 2.00); all P < 0.05. In this multicenter study, 44% of children hospitalized with SARS-CoV-2-related conditions experienced neurological manifestations, which were associated with ICU admission and pre-existing neurological condition. Posthospital assessment for, and support of, functional impairment and neuroprotective strategies are vitally needed.